Dextromethorphan Dosing Recommendations
Standard Dosing
For adults and children ≥12 years, use 10 mL (30 mg dextromethorphan polistirex equivalent) every 12 hours, not exceeding 20 mL in 24 hours; for children 6 to <12 years, use 5 mL every 12 hours (maximum 10 mL/24 hours); for children 4 to <6 years, use 2.5 mL every 12 hours (maximum 5 mL/24 hours); and do not use in children under 4 years. 1
Age-Based Dosing (FDA-Approved)
- Adults and children ≥12 years: 10 mL every 12 hours (maximum 20 mL/24 hours)
- Children 6 to <12 years: 5 mL every 12 hours (maximum 10 mL/24 hours)
- Children 4 to <6 years: 2.5 mL every 12 hours (maximum 5 mL/24 hours)
- Children <4 years: Contraindicated 1
The FDA formulation contains dextromethorphan polistirex equivalent to 30 mg dextromethorphan hydrobromide per 5 mL 1, providing extended 12-hour relief 1.
Clinical Efficacy Context
Dextromethorphan is recommended only for chronic bronchitis, not for upper respiratory infections (URIs) or acute cough. The 2006 CHEST guidelines provide a Grade B recommendation (fair evidence, intermediate benefit) for dextromethorphan in chronic bronchitis but explicitly state Grade D (good evidence, no benefit) for URI-associated cough 2. This is critical: despite widespread use, dextromethorphan has limited to no efficacy for common cold-related cough.
When to Use vs. Avoid
Use dextromethorphan for:
- Chronic bronchitis with symptomatic cough requiring short-term relief 2
- Acute bronchitis (peripheral suppressants preferred, but dextromethorphan acceptable) 2
Do NOT use dextromethorphan for:
- Cough due to URI/common cold (ineffective) 2
- Children <4 years (FDA contraindication) 1
- Children with acute cough (minimal benefit, potential adverse events) 3
Pediatric Considerations
The 2020 CHEST pediatric guidelines strongly advise against OTC cough medications including dextromethorphan in children due to lack of efficacy and potential for adverse events, including reported deaths from toxicity. 3 The FDA subsequently restricted prescription opioid cough medications to adults ≥18 years in 2018, and manufacturers voluntarily labeled OTC products "do not use in children under 4 years" 3.
Pediatric Evidence Gaps
Research shows conflicting results. One 2023 study demonstrated 21-25% reduction in objective cough frequency with dextromethorphan versus placebo in children 6-11 years 4, while a 2000 study found no clinically significant antitussive activity at 30 mg doses 5. A 2004 dose-response study suggested potential benefit at 0.5 mg/kg but noted increased adverse events at higher doses 6.
For children with acute cough, honey offers more relief than dextromethorphan or placebo (though not superior to dextromethorphan specifically) 3.
Hepatic Impairment
Exercise greater caution with dextromethorphan in patients with liver impairment or post-liver transplant. 7 While specific dose adjustments are not established in FDA labeling, dextromethorphan undergoes hepatic metabolism via CYP2D6. In transplant recipients, dextromethorphan can be used but requires additional monitoring in those with hepatic dysfunction 7.
Critical Safety Warnings
Toxicity Thresholds
- Ingestions of 5-7.5 mg/kg: Poison center follow-up every 2 hours for 4 hours 8
- Ingestions >7.5 mg/kg: Refer to emergency department 8
- Suicidal intent or intentional abuse: Immediate emergency department referral 8
Drug Interactions
Avoid or monitor closely when combined with:
- MAO inhibitors or SSRIs: Risk of serotonin syndrome; requires follow-up every 2 hours for 8 hours 8
- Cyclosporine (in transplant patients): Diphenhydramine requires additional monitoring, but dextromethorphan is safer 7
Contraindications
- Children <4 years 1
- Patients with sulfite allergies (formulations contain sodium metabisulfite) 1
- Concurrent MAO inhibitor use (serotonin syndrome risk) 8
Common Pitfalls
Prescribing for viral URI cough: This is the most common misuse. Dextromethorphan has no proven benefit for common cold cough despite widespread belief 2, 5.
Using in young children: The risk-benefit ratio is unfavorable given lack of efficacy and potential for serious adverse events including death 3.
Ignoring drug interactions: Particularly dangerous with serotonergic medications 8.
Assuming weight-based dosing: FDA dosing is age-based, which creates variability (0.35-0.94 mg/kg range) 6, but this is the approved standard 1.